Literature DB >> 24478045

Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis.

Vincent Ruland1, Stefan Hartung, Uwe Kordes, Johannes E Wolff, Werner Paulus, Martin Hasselblatt.   

Abstract

Choroid plexus carcinoma is a malignant brain tumor predominantly occurring in young children. Only limited data are available regarding the underlying molecular genetic alterations. Therefore, molecular inversion probe single nucleotide polymorphism (MIP SNP) arrays were performed on a series of 26 neuropathologically well-characterized choroid plexus carcinomas. Recurrent copy number losses of chromosomes 5, 6, 16, 18, 19, and 22 as well as gains of chromosomes 1, 2, 4, 12, and 20 were identified. Furthermore, GISTIC analysis identified significant recurrent gains of 17 genes in 9 regions, and recurrent losses of 96 genes in 14 regions. Clustering analysis separated choroid plexus carcinomas into two groups: one characterized by marked losses and the other characterized by gains across the chromosomes. Chromosomal losses of 9, 19p, and 22q were significantly more frequent in younger children (<36 months), whereas gains on chromosomes 7 and 19, and chromosome arms 8q, 14q, and 21q prevailed in older patients. Multivariate analysis revealed that loss of 12q was associated with shorter survival [12 ± 5 months vs. 86 ± 8 months; (mean ± SD; P = 0.001)] and, in addition, 45 smaller chromosomal regions showing genetic alterations significantly associated with survival could be identified. The MIP SNP array profiles also contributed to the diagnosis of two difficult SMARCB1-negative tumors as choroid plexus carcinoma and cribriform neuroepithelial tumor (CRINET), respectively. In conclusion, choroid plexus carcinomas are characterized by complex genetic alterations, which are related to patient age and may have prognostic and diagnostic value.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24478045     DOI: 10.1002/gcc.22148

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Authors:  Jun Wang; Diana M Merino; Nicholas Light; Brian L Murphy; Yong-Dong Wang; Xiaohui Guo; Andrew P Hodges; Lianne Q Chau; Kun-Wei Liu; Girish Dhall; Shahab Asgharzadeh; Erin N Kiehna; Ryan J Shirey; Kim D Janda; Michael D Taylor; David Malkin; David W Ellison; Scott R VandenBerg; Charles G Eberhart; Rosalie C Sears; Martine F Roussel; Richard J Gilbertson; Robert J Wechsler-Reya
Journal:  Cancer Res       Date:  2019-03-18       Impact factor: 12.701

2.  Methylation of the hTERT promoter is frequent in choroid plexus tumors but not of independent prognostic value.

Authors:  Vincent Ruland; Stefan Hartung; Uwe Kordes; Johannes E Wolff; Werner Paulus; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2014-05-14       Impact factor: 4.130

3.  A new genetically engineered mouse model of choroid plexus carcinoma.

Authors:  Salsabiel El Nagar; Frederique Zindy; Charlotte Moens; Luc Martin; Damien Plassard; Martine F Roussel; Thomas Lamonerie; Nathalie Billon
Journal:  Biochem Biophys Res Commun       Date:  2018-01-12       Impact factor: 3.575

4.  Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes.

Authors:  Yiai Tong; Diana Merino; Birgit Nimmervoll; Kirti Gupta; Yong-Dong Wang; David Finkelstein; James Dalton; David W Ellison; Xiaotu Ma; Jinghui Zhang; David Malkin; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

5.  A French retrospective study on clinical outcome in 102 choroid plexus tumors in children.

Authors:  A Siegfried; S Morin; C Munzer; M B Delisle; M Gambart; S Puget; C A Maurage; C Miquel; C Dufour; P Leblond; N André; D Figarella Branger; J Kanold; J-L Kemeny; C Icher; A Vital; E Uro Coste; A I Bertozzi
Journal:  J Neurooncol       Date:  2017-07-04       Impact factor: 4.130

6.  Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups.

Authors:  Christian Thomas; Martin Sill; Vincent Ruland; Anika Witten; Stefan Hartung; Uwe Kordes; Astrid Jeibmann; Rudi Beschorner; Kathy Keyvani; Markus Bergmann; Michel Mittelbronn; Torsten Pietsch; Jörg Felsberg; Camelia M Monoranu; Pascale Varlet; Peter Hauser; Adriana Olar; Richard G Grundy; Johannes E Wolff; Andrey Korshunov; David T Jones; Melanie Bewerunge-Hudler; Volker Hovestadt; Andreas von Deimling; Stefan M Pfister; Werner Paulus; David Capper; Martin Hasselblatt
Journal:  Neuro Oncol       Date:  2016-01-28       Impact factor: 12.300

7.  Choroid plexus carcinoma in adults: an extremely rare case.

Authors:  Selcuk Ozdogan; Yusuf Emrah Gergin; Sinem Gergin; Ozgur Senol; Mehmet Tiryaki; Necati Tatarli; Tufan Hicdonmez
Journal:  Pan Afr Med J       Date:  2015-03-30

8.  Management of choroid plexus tumors-an institutional experience.

Authors:  Arthur Hosmann; Felix Hinker; Christian Dorfer; Irene Slavc; Christine Haberler; Karin Dieckmann; Engelbert Knosp; Thomas Czech
Journal:  Acta Neurochir (Wien)       Date:  2019-02-19       Impact factor: 2.216

9.  Sonic Hedgehog promotes proliferation of Notch-dependent monociliated choroid plexus tumour cells.

Authors:  Li Li; Katie B Grausam; Jun Wang; Melody P Lun; Jasmin Ohli; Hart G W Lidov; Monica L Calicchio; Erliang Zeng; Jeffrey L Salisbury; Robert J Wechsler-Reya; Maria K Lehtinen; Ulrich Schüller; Haotian Zhao
Journal:  Nat Cell Biol       Date:  2016-03-21       Impact factor: 28.824

10.  Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma.

Authors:  Albert Cornelius; Jessica Foley; Jeffrey Bond; Abhinav B Nagulapally; Julie Steinbrecher; William P D Hendricks; Maria Rich; Sangeeta Yendrembam; Genevieve Bergendahl; Jeffrey M Trent; Giselle S Sholler
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.